News/Events

Stay up-to-date on the world of marine Omega-3s and everything Epax.

Correct Form of Measurement

Omega-3 Fatty Acids:

Correct Form of Measurement

The Global Organization for EPA and DHA Omega-3s (GOED) recently released an industry advisory on the correct way of measuring EPA and DHA. Whilst Area % historically was the standard measurement of the Omega-3 fatty acid content, Epax chose to replace this for the far more accurate weight measurement (mg/g) several years ago. In fact, all new products launched by Epax the past 5 years solely use mg/g unless where an addition of A% has been specifically required by the customer. We support GOED's effort to establish mg/g as the standard form of measurement. The new industry advisory can be found here.

Reduced Limit for Lead

GOED Voluntary Monograph

Reduced Limit for Lead

The members of GOED recently voted to reduce the maximum limit on lead from 0.1 to 0.05 mg/kg in the GOED Voluntary Monograph. In order to furter support a positive development for the Omega-3 industry, Epax was one of the members voting for this change. The new limit will be valid from March 1, 2019. 

For Epax’ products and customers there will be no specification change required, as we already implemented a maximum limit of 0.025 mg/kg back in 2009-2010.  

Nordic Lipidforum Seminar

Epax to present at

Nordic Lipidforum Seminar

Our R&D Manager Iren Stoknes and our Product Marketing Manager Sarah Christianslund will present at Nordic Lipidforum's seminar 'High Quality Lipid Products – lipid oxidation and sensory properties'. 

Join us in Ålesund October 24 and 25!

http://lipidforum.info/

relaunch

GOED website 'Fats of Life'

relaunch

The Global Organization for EPA and DHA Omega-3s (GOED) has relaunched its Omega-3 science hub 'Fats of Life'. This site is specifically designed for healthcare professionals, offering an easy way of accessing high-quality scientific data on the use of EPA and DHA Omega-3 for various health conditions/concerns. 

Check it out here: www.fatsoflife.com

Epax is proud to be a founding member of GOED! 

Q2 2018

Pelagia financial results

Q2 2018

Pelagia - Epax' owner - recently released its results for Q2 2018.

Visit Pelagia's webpage for more information! 

Epax is growing

We're looking to fill several new positions

Epax is growing

UPDATE: Application deadline has now passed. 

We currently have 2 positions open at our facility in Ålesund, Norway. Join one of the best teams in the Omega-3 industry!  



Epax to exhibit at Vitafoods Asia

Meet us!

Epax to exhibit at Vitafoods Asia

Epax Norway AS is set to exhibit at Vitafoods Asia September 11-12 at the Sands Expo & Convention Centre at Marina Bay Sands in Singapore. Visit us at stand J30 on the GOED Pavilion for a chat about Omega-3!

PUFA level and acute venous thromboembolism

New Omega-3 research

PUFA level and acute venous thromboembolism

Hiki M et al. have studied the significance of serum polyunsaturated fatty acid level imbalance in patients with acute venous thromboembolism, and our key takeway is that high serum AA levels and low EPA levels are associated with the development of acute VTE, suggesting that the imbalance of PUFAs may be a potential therapeutic target for preventing acute VTE.

Background: Polyunsaturated fatty acids (PUFAs) take part in various biological events linked to the pathogenesis of venous thromboembolism (VTE), including inflammation, endothelial dysfunction, and hypercoagulability. Several studies have demonstrated the association between PUFAs and the occurrence of VTE.

Design: 45 patients with acute VTE were enrolled to examine their PUFA levels. 37 age-, gender-, and body mass index-matched healthy volunteers were controls. Serum omega 3 (eicosapentaenoic acid: EPA and docosahexaenoic acid: DHA) and omega 6 (dihomogammalinolenic acid: DGLA and arachidonic acid: AA) fatty acids levels were measured within 24 h of admission.

Results: Patients with VTE showed significantly higher AA and lower EPA levels, and lower EPA/AA ratios than the controls. Multivariate analysis revealed that AA was an independent marker for VTE. When the patients were divided based on their median age (58 years old) the younger patients with VTE showed significantly lower EPA/AA levels than their age-matched controls, whereas older patients with VTE showed a significantly higher AA/DGLA levels than the older controls. 

Source: Journal of atherosclerosis and thrombosis 2017;24:1016-1022

Load more